Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Dose-finding Study Of Docetaxel And Doxorubicin In First-line Treatment Of Patients With Metastatic Breast Cancer.
J. L. Misset, V. Diéras, G. Gruia, H. Bourgeois, E. Cvitkovic, S. Kalla, L. Bozec, P. Beuzeboc, C. Jasmin, J. Aussel, A. Riva, N. Azli, P. Pouillart
Published 1999 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
PURPOSE To determine the maximum tolerated dose (MTD), the dose-limiting toxicity (DLT) and the recommended dose of docetaxel in combination with doxorubicin, and to evaluate the activity in patients with advanced breast cancer. PATIENTS AND METHODS Forty-two women with untreated metastatic breast cancer (79% with visceral metastases; 52% with prior adjuvant anthracycline therapy) were treated with doxorubicin (40-60 mg/m2) i.v. bolus followed one hour later by docetaxel (50-85 mg/m2) one-hour i.v. infusion every three weeks, without G-CSF support. RESULTS The MTD occurred at the dose level combining 85 mg/m2 of docetaxel and 50 mg/m2 of doxorubicin, with the DLT being neutropenic sepsis. Neutropenia and/or its complications were manageable and no grade 3-4 or severe non-hematological toxicities were observed. Fluid retention was frequent but never severe. With a median cumulative dose of doxorubicin of 392 mg/m2 (240-559 mg/m2) and a median follow-up time of 29 months (9(+)-41), no congestive heart failure was observed. High activity was observed at all dose levels, particularly the last four, with a response rate of 81% (95% confidence interval (95% CI): 62.5-92.5). Median time to progression was 46 weeks (6(+)-62). Two-year survival was 66%, and median survival has not yet been reached. CONCLUSIONS Docetaxel-doxorubicin is feasible, safe and highly active. The incidence of febrile neutropenia without G-CSF requires careful monitoring but is acceptable in this setting. There does not appear to be an increase in the cardiac toxicity of doxorubicin. The recommended doses is either docetaxel 75 mg/m2 and doxorubicin 50 mg/m2 or docetaxel 60 mg/m2 and doxorubicin 60 mg/m2, administered every three weeks.
This paper references
Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer.
J. Fisherman (1996)
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
C. Hudis (1996)
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
M. Venturini (1996)
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
Paclitaxel + doxorubicin in metastatic breast cancer: The Milan experience
L Gianni (1998)
Anthracyclines. In Chabner BA, Collins JM (eds): Cancer Chemotherapy: Principles and Practice, second edition
CE Myers (1990)
In vivo evaluation of Taxotere (RP 56976, NSC 628503) in combination with cisplatinum , doxorubicin or vincristine
Mc Bissery (1992)
Phase I—II study of 72-hour infusion paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer
Js Fisherman (1996)
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
R. G. Schwartz (1987)
Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic.
J. Gehl (1996)
Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.
G. Sledge (1994)
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
V. Valero (1995)
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
B. Chevallier (1995)
Reporting results of cancer treatment
A. Miller (1981)
A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.
P. Fumoleau (1996)
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
P. Ravdin (1995)
Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study Group.
J. Bonneterre (1993)
Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.
J. Alexander (1979)
Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer.
F. Holmes (1996)
R. A. Smith (1951)
Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.
L. Gianni (1997)
Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.
M. Bissery (1995)
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
L. Gianni (1995)
Schedule dependent pharmacokinetics (PK) in a phase I trial of Taxol (T) and doxorubicin (D) as initial chemotherapy for metastatic breast cancer
Fa Holmes (1994)
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant metastatic breast cancer
Pm Ravdin (1995)
Adriamycin (NSC 123127) cardiomyopathy. An overview with determination of risk factors
R. A. Minow (1975)
Doxorubicin (Dox) and Taxotere® (Txt) -a pharmacokinetic (Pk) study of the combination in advanced breast cancer
J Schiiller (790)
Taxotere (T) does not change the pharmacokinetic (PK) profile of Doxorubicin (Dox) and Doxorubicinol (Dx-ol)
R Bellott (1998)
Cancer Chemotherapy: Principles and Practice, second edition
Ce Myers (1990)
Coping with toxicities of docetaxel (Taxotere).
D. Schrijvers (1993)
Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience.
A. V. van Oosterom (1995)
Final results of a phase II study of Taxotere (T), doxorubicin (A) and cyclophosphamide (C) (TAC) as 1st line CT in metastatic breast cancer patients
J-M Nabholtz (1998)
Efficacy and safety of different corticosteroid (C) premedications (P) in breast cancer (BC) patient (pts) treated with Taxotere® (T)
A Riva (660)
MD Hopital Paul Brousse 14-16 Avenue Paul Vaillant Couturier BP200 94804 VillejuifCedex France E-mail: firstname.lastname@example.org
Phase I study of Taxol (T) and doxorubicin (D) with G-CSF in patients (PT) without prior chemotherapy (CT) for metastatic breast cancer (MBC)
Fa Holmes (1160)
Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
M. Trudeau (1996)
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: A seven-year experience using radionuclide angiocardiography
Rg Schwartz (1987)
Phase I — II study of 72 - hour infusion paclitaxel and doxorubicin with granulocyte colony - stimulating factor in patients with metastatic breast can
JS Fisherman (1996)
This paper is referenced by
A phase II study of sequential docetaxel followed by doxorubicin/cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
A. Antón (2003)
Infusional ECarboF in patients with advanced breast cancer: a very active and well-tolerated out-patient regimen.
A. Hügli (2000)
Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer.
J. Sparano (2001)
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
H. Roché (2006)
Introducing taxanes in the adjuvant treatment of breast cancer: expectations and reality.
M. Colleoni (2000)
A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
E. Perez (2002)
Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination.
T. Granda (2001)
Docetaxel: use in non—small cell lung cancer and metastatic breast cancer and formulation update
J. Crown (2000)
A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.
A. Di Leo (2000)
Granulocyte Colony-Stimulating Factor Use in Patients With Chemotherapy-Induced Neutropenia : Review
M. Rader (2017)
Docetaxel: an update of its use in advanced breast cancer.
D. Figgitt (2000)
Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
J. Nabholtz (2001)
The choice of adjuvant combination therapies with taxanes: rationale and issues addressed in ongoing studies.
J. Nabholtz (2001)
Indicaciones de quimioterapia en cáncer de mama
J. Ferreiro (2000)
Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study.
A. Alexopoulos (2001)
Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer.
G. Lunardi (2002)
Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer.
G. Ganem (2003)
Dose Escalation Study of Epirubicin and Docetaxel in Patients with Advanced or Recurrent Breast Cancer
Ichiro Ichinose (2008)
NSABP breast cancer clinical trials: recent results and future directions.
E. Mamounas (2003)
The effect of the nitroxide pirolin on oxidative stress induced by doxorubicin and taxanes in the rat brain.
S. Tabaczar (2017)
Phase II Study of Concurrent Administration of Doxorubicin and Docetaxel as First-Line Chemotherapy for Metastatic Breast Cancer
T. Aihara (2003)
Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?
J. Klastersky (2011)
Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia.
L. Biganzoli (2004)
Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer.
D. Khayat (2001)
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.
C. Vogel (2005)
Phase I trial of liposomal encapsulated doxorubicin (Myocet; D-99) and weekly docetaxel in advanced breast cancer patients.
E. Mrózek (2005)
Docetaxel–Anthracycline Combinations in Metastatic Breast Cancer
Jean-Marc A. Nabholtz (2004)
Novel Approaches in the Early Treatment of Breast Cancer
M. Aapro (2001)
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
G. Minotti (2004)
Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer.
M. Venturini (2002)
Epirubicin‐Docetaxel Combination in First‐Line Chemotherapy for Patients With Metastatic Breast Cancer: Final Results of a Dose‐Finding and Efficacy Study
P. Viens (2001)
Highlights From: 23rd Annual San Antonio Breast Cancer Symposium
S. Antonio (2001)See more